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Implications of evidence-based understanding of 
benefits and risks for cancer prevention strategy
As the second leading cause of death worldwide, 
cancer has posed enormous burden to patients, their 
families, and the society as a whole. The shift from 
cancer treatment to prevention, with an emphasis 
on coordinated multisectoral actions, has become a 
global trend.
 The Hong Kong Cancer Strategy 20191 recently 
released by the Hong Kong SAR Government is the 
first holistic plan to upscale cancer prevention and 
control in Hong Kong. Target outcomes of the seven 
aspects in the Strategy are expected to be achieved 
by 2025. The key strategies set for cancer prevention 
include reducing risk factors, providing population-
based cancer screening based on evidence, seeking 
early detection and diagnosis, and strengthening 
primary healthcare services in Hong Kong. Globally, 
the UK has long been featured by its expanding role 
of primary care in cancer prevention.2 Meanwhile, 
primary care is also being promoted increasingly 
in mainland China,3 where a community-based 
longitudinal study is in progress. Patients’ adherence 
to healthy lifestyles is being followed up within 
the context of family doctor team–led activities to 
prevent long-term conditions that share common 
risk factors with cancer.
 To date, a substantial body of research evidence 
in primary prevention of cancer has confirmed that 
modifiable lifestyles such as tobacco consumption, 
alcohol use, poor diet, physical inactivity, and 
overweight and obesity are associated with cancers, 
such as colorectal, lung, breast, prostate, and liver 
cancer, that are prevalent locally and internationally. 
Infections, exposure to environmental and 
occupational carcinogens, and exposure to radiation 
are also important in cancer development. Public 
health education and health policies that encourage 
healthy (or discourage unhealthy) behavioural 
practices can greatly benefit the prevention of cancer. 
Evidence from the UK suggested that approximately 
4 in 10 cancer cases could be prevented through 
behavioural changes alone.4-6 Furthermore, a 
widespread adoption of vaccination administration 
approach, such as universal vaccination against 
hepatitis B virus that has been part of the Hong 
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Kong Childhood Immunisation Programme for 30 
years, has shown to be safe and most cost-effective in 
reducing the incidence of liver cancer. Most recently, 
eligible female primary school students of suitable 
ages will be provided with human papillomavirus 
vaccination, starting from the 2019/20 school year, 
as evidence supports this vaccination strategy as 
effective in reducing the incidence of cervical cancer.
 Of equal importance is the secondary 
prevention of cancer that aims to detect cancer at 
an early stage when treatment is more effective. 
Cancer screening and early detection is inevitably a 
multi-determined field with complexity illustrated by 
the overriding concern on whether screening does 
more good than harm to individuals and to society. 
Recommendations and controversies on the benefits 
and downsides of prevention and screening strategy 
have been brought to the public’s attention with 
regard to cervical cancer,7 colorectal cancer,8 and 
breast cancer.9-12 At present, the cervical screening 
programme and the colorectal cancer screening 
programme are the two territory-wide strategies 
regularised in Hong Kong based on current evidence.1 
It is recommended that Hong Kong individuals aged 
50 to 75 years with average risk for colorectal cancer 
should consult their physicians to consider either one 
of the three screening modalities (faecal occult blood 
test, sigmoidoscopy, or colonoscopy) at different 
screening intervals. This is consistent with UK policy, 
where asymptomatic individuals who are at average 
risk and aged ≥50 years are provided with flexible 
sigmoidoscopy and faecal occult blood test.2 On 
certain types of cancers such as breast cancer, most 
criticisms of the screening are related to unfavourable 
cost-effectiveness, false-positive (or false-negative) 
results, overdiagnosis, overtreatment, complications 
arising from subsequent invasive procedures, and 
psychological distress.9 Therefore, population-based 
mammography screening still requires more robust 
evidence to ascertain the screening appropriateness 
for asymptotic women at average risk. For prostate 
cancer, recent evidence of its incidence and mortality 
highlights the potential influence of cancer screening 
and diagnostic ascertainment on geographic 
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variations.13 A local study conducted among Chinese 
patients with prostate cancer14 reported that patients 
who presented with cancer-related symptoms had 
more metastatic disease and poorer prognosis than 
asymptomatic individuals who were diagnosed by an 
opportunistic case-finding preventive approach. This 
implied the importance of screening methodology in 
secondary prevention of cancer. 
 In this issue of the Hong Kong Medical Journal, 
Cheng et al15 examined incidence and types of 
complications and associated predictive factors 
for transrectal ultrasound-guided (TRUS) biopsy 
in diagnosing suspected prostate cancer. In their 
retrospective cohort study, the authors demonstrated 
a satisfactorily low level of overall post-biopsy 
complications that required subsequent visits to 
emergency departments or hospital admissions. 
Their findings support the use of TRUS biopsy as a 
safe procedure for diagnosing suspected prostate 
cancer. Although these findings from Hong Kong may 
not be readily generalisable to Western populations, 
they are compatible with guidelines released by 
the British Association of Urological Surgeons and 
the British Association of Urological Nurses that 
support the use of TRUS biopsy in early detection 
given its widespread availability, affordability, and 
easy-to-learn procedure.16 The UK National Institute 
for Health and Care Excellence recommends that 
physicians should explain the risks and benefits 
to patients with adequate time for informed 
consideration.17 As suggested by Cheng et al,15 more 
evidence generated from a multicentre study in the 
wider Asian population would be valuable to offer 
a comprehensive picture of the magnitude of the 
complications.
 A methodological highlight of Cheng et al’s 
study15 is the investigation performed on the basis of 
a territory-wide centralised electronic patient record 
system in Hong Kong. In the UK, electronic clinical 
decision support has been in use for adult cancer. 
Primary care clinical computers are integrated with 
diagnostic software, which can automatically search 
the records for relevant entries with an absolute 
cancer risk estimated.2 As advocated in The Hong 
Kong Cancer Strategy 2019, the application of big 
data analytics should be given a priority to examine 
clinical information for better management of cancer 
patients.
 Improvements in cancer detection and patient 
outcome, with reduced mortality, are the prime goal 
of cancer prevention. Emphasis on the individuals’ 
continuous engagement in their care should be placed 
across the cancer continuum with enhanced capacity 
and expertise support. Primary prevention remains 
the single most effective and efficient strategy in both 
clinical and community settings for many decades. 
Secondary prevention, despite holding the potential 
for reduced morbidity and mortality through 
concentrated efforts in screening and early detection, 
requires more cutting-edge science and high-quality 
data to ascertain the appropriateness at each risk 
stratum. The government should be proactive in 
developing structured cancer screening programmes, 
based on up-to-date and robust evidence confirming 
that the benefits outweigh risks and harms, and ensure 
adequate coverage for the target population. Cancer 
screening interventions that remain controversial 
should be subject to individualised consideration and 
undergo rigorous risk-benefit assessments before 
being recommended for implementation on a wider 
scale. Meanwhile, emphasis should be made on 
individual preferences and shared decision making 
with sufficient discussions that detail the benefits, 
uncertainties, and possible complications to patients, 
their families and carers.
 The future of cancer prevention is challenging 
but promising. We look forward to a growing body 
of scientific work that can further advance the 
understanding of benefits and risks arising from 
emerging strategies and novel technologies in cancer 
prevention. Knowledge accumulated and transferred 
from evidence-based studies will ultimately help 
achieve the vision and mission of The Hong Kong 
Cancer Strategy 2019.
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